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ABSTRACT 
A reappraisal of the major advances in the diagnostic pathology of adrenal cortical lesions and 
tumors in the last 25 years is presented, with special reference to the definition of malignancy in 
primary adrenal cancer and its variants. Slightly more than 25 years ago Weiss proposed his 
diagnostic scoring system for adrenal cortical carcinoma. This represented a milestone for adrenal 
pathologists and the starting point for further modifications of the system, either through minor 
changes in the scoring procedure itself, or concentrating on some particular Weiss criterion such 
as mitotic index, integrated into alternative scoring schemes or algorithms that are currently 
under validation. Improvements in diagnostic immunohistochemistry have led to the identification 
of markers of cortical origin, such as Melan A, alpha-inhibin and SF-1 and of prognostic factors in 
carcinoma, such as the Ki-67 proliferation index and SF-1 itself. With regard to hyperplastic 
conditions, genetic investigations have allowed the association of the majority of cases of primary 
pigmented nodular adrenocortical disease (PPNAD) in Carney complex to mutations in the gene 
encoding the regulatory subunit 1A of protein kinase A (PRKAR1A). Other hereditary conditions 
are also associated with adrenal cortical tumors, including the Li-Fraumeni, Beckwith-Wiedemann, 
Gardner, Multiple Endocrine Neoplasia type 1 and Neurofibromatosis type 1 syndromes. 
Moreover, several advances have been made in the knowledge of the molecular background of 
sporadic tumors, and a number of molecules/genes are of particular interest as potential 
diagnostic and prognostic biomarkers.  
 
KEY WORDS: Adrenal cortex, pathology, adenoma, carcinoma, diagnostic criteria, update  
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INTRODUCTION: Where we were 
 
Diagnostic pathology of adrenal cortical diseases classically included diffuse lesions and single or 
multiple nodular conditions. In this respect, the diagnostic approach has not undergone major 
changes in the past 25 years, but several new tools have become available for the purpose of 
better identifying different diseases and tumor categories. Light microscopy and 
immunophenotyping or molecular markers have led to the definition of more accurate and 
reproducible categories of adrenal cortical disorders, especially in neoplastic diseases. 
Twenty-five years ago, pathology reports were based on few terms (mainly hyperplasia, adenoma, 
carcinoma or metastasis) and a description of the relevant pathological features was attached, 
according to local practice of different countries and institutions. Electron microscopy was 
generally not necessary for subtyping adrenal cortical diseases and immunohistochemical 
diagnostic markers related to adrenal cortex were very limited, and no prognostic or predictive 
markers were known. However, as for other types of human diseases, pathology of the adrenal 
cortex has progressed - especially in the most recent years - together with the improvement of the 
clinical diagnosis and management of patients, and with the technical implementation of ancillary 
tools.  
This overview will summarize the major advances in the diagnosis of adrenal cortical lesions, 
separately approaching diagnostic, immunophenotypic and molecular data that have emerged in 
the past 25 years, focusing on adrenal cortical tumors and on novel insights that have improved 
the diagnostic work-up or are currently being validated. A summary of the most relevant 
achievements is illustrated in Figure 1. 
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DIAGNOSTIC CRITERIA OF MALIGNANCY 
 
Twenty-five years ago several parameters of malignancy had been identified, all having a poor 
sensitivity for adrenal cortical carcinoma diagnosis. As a result, Weiss proposed combining some of 
them into a scoring system. This proposal (the Weiss Score) was a major advance in adrenal 
cortical cancer pathology and still represents - in its original proposal [1,2] or after minor 
modifications  [3] - a milestone in this field. However, the effects of a 25 year-long application of 
the Weiss Score, as also discussed by Weiss himself in a recent reappraisal of his score [4], led to 
the recognition that the relevance and reproducibility of the individual parameters varies.  
As a direct consequence of this situation, alternative diagnostic protocols or algorithms have 
emerged in the last decades, all having a limited application and a lower popularity compared to 
Weiss Score, at least until recent years. As a matter of fact, all systems used for adrenal cortical 
carcinoma diagnosis largely rely on mitotic figures count, which thus represents the most relevant 
and accurate parameter to assess malignancy in adrenal cortical tumors, irrespective of the 
diagnostic protocol applied. In this respect, Diaz-Cano and Blanes proposed a diagnostic algorithm 
based on the mitotic count, and suggested that a cut-off value of >5 mitotic figures in 50 high 
power fields was associated per se with malignant behavior [5]. Among other alternative 
approaches, an algorithm was recently designed to combine architectural features (namely the 
disruption of the reticulin framework) and the presence of malignancy-related parameters already 
included in the Weiss Score, such as increased mitotic index and the presence of necrosis and 
vascular invasion [6] (Figure 2). This algorithm was able to reclassify with a 100% sensitivity and 
specificity all cases with a “malignant” Weiss Score (>3) and is generally simple and easier to apply. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 5 
 
In addition, in subsequent publications, it proved applicable also in specific adrenal cortical tumor 
variants, namely the myxoid and the oncocytic subtypes (see also below) [7,8].  
On the other hand, it soon became clear that some parameters proposed in the Weiss Score 
(including sinusoidal invasion, diffuse growth, etc) were difficult to apply and lacked inter-observer 
eproducibility . These difficulties were eventually addressed in a recent study reported by a French 
group [9], which definitely demonstrated that not all Weiss criteria are easily applicable and that 
pathologists’ training is crucial in improving the diagnostic accuracy. Moreover, in a recent study 
the reproducibility of reticulin staining - which is the key parameter of the algorithm described 
above - was also tested among observers of different centers that blindly examined over 240 
adrenal cortical tumors; the assessment of reticulin disruption was highly reproducible among 
pathologists, especially after specific training and in cases classified as malignant according to the 
Weiss Score [10]. 
 
SPECIAL TYPES OF ADRENAL CORTICAL TUMORS 
 
Oncocytic adrenal cortical tumors.  
Oncocytic adrenal cortical neoplasms represent a subset of tumors with a predominant 
component of usually large cells with the cytoplasm filled with mitochondria which confer a 
granular and deeply eosinophilic appearance. Since the first report in 1986 [11], many case reports 
or small series have been published. In the series collected at our Institution, the prevalence of 
oncocytic adrenal cortical carcinomas among malignant tumors was approximately 18% [8]. 
Oncocytic adrenal cortical neoplasms may be classified into “pure” if made of >90% oncocytes, 
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mixed if oncocytes are present in 50% to 90% of the tumor, and focal if the oncocytic component 
accounts for less than 50%. As originally stated by Bisceglia et al. [12], the diagnosis of malignancy 
in oncocytic tumors is difficult using the classical Weiss Score, since at least three parameters 
(eosinophilic cytoplasm, high nuclear grade and diffuse architecture) are intrinsically present in 
this tumor type, irrespective of the biological and clinical behavior. As a consequence, the cut-off 
values validated for conventional adrenal cortical carcinoma may lead to an over-diagnosis of 
malignancy in this special group. For this reason, exclusively for purely oncocytic tumors, an 
alternative diagnostic system was proposed based on criteria specific for this tumor type: any of 
the three “major criteria” (mitotic rate >5 per 50HPF, atypical mitoses, and venous invasion) 
defines an oncocytic adrenal cortical carcinoma, whereas one to four “minor criteria” (necrosis, 
capsular and sinusoidal invasion, size >10 cm or weight >200 g) defines an oncocytic adrenal 
cortical neoplasm of borderline malignancy [12], A retrospective survival analysis provided by 
Wong and coworkers [13] showed that this classification correctly predicted the malignant 
potential of these tumors and demonstrated a generally better prognosis for oncocytic carcinomas 
in comparison with those of the classical type. A further study claimed that the reticulin algorithm 
correctly stratifies oncocytic adrenal cortical tumors into benign and malignant, and confirmed the 
“low grade” malignancy for these tumors, as also supported by low mean mitotic and Ki-67 
indexes [8]. Moreover, as for oncocytic neoplasms at other sites [14,15], the mitochondrial DNA 
“common deletion” (4977 base pairs) was identified in approximately 40% of oncocytic adrenal 
cortical tumors, more commonly in borderline or benign tumors, but not in control adrenal 
cortical carcinomas of the classical type [8]. 
 
Myxoid adrenal cortical tumors.  
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Description of myxoid adrenal cortical tumors dates back to 1979 [16] and these neoplasms are 
characterized by extracellular deposits of myxoid material, highlighted by positive Alcian-Blue 
staining, which can be predominant in a subset of approximately 10% of ACC [7,17]. Among them, 
two groups can be identified based on architectural and cytological features, irrespective of the 
amount of myxoid material: group 1 tumors are characterized by monotonous cells of small to 
medium size, with mild to moderate nuclear atypia and scant, lightly eosinophilic cytoplasm, 
growing in a trabecular, pseudoglandular or cribriform pattern; conversely, group 2 tumors are 
more similar to classical adrenal cortical carcinomas, comprising large pleomorphic cells with a 
moderate to high nuclear atypia and abundant eosinophilic cytoplasm, growing in a diffuse 
pattern and usually having focal myxoid areas (< 20% of the total area) within an otherwise 
conventional adrenal cancer. Although some cases show a certain degree of overlapping features 
between these two groups, group 2 tumors are probably the result of degenerative myxoid 
changes in conventional adrenal cortical carcinomas and we suggest that should not be classified 
into this distinctive variant of adrenal cortical tumors.  
Based on the aforementioned pathological features, the myxoid variant is challenging for several 
reasons. The first is the differential diagnosis, especially in biopsy material, with other myxoid 
neoplasms, such as extra-skeletal myxoid chondrosarcoma, chordoma, myxoid carcinomas from 
the kidney or other sites, myxoid lipomatous or nerve sheath tumours. Secondly, the distinction 
between benign and malignant adrenal cortical myxoid tumors may be difficult. Due to the above-
mentioned cyto-architectural characteristics, myxoid tumors often lack two of the Weiss 
parameters (diffuse growth and nuclear atypia) and the identification of invasive areas might be 
hard or equivocal in the presence of abundant myxoid background. Therefore, in adrenal tumors 
with predominant myxoid stroma it is advisable to consider malignancy even in tumors with a low 
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grade appearance. Moreover, in terms of prognosis, it has also been suggested that myxoid 
adrenal cortical carcinomas may have a more aggressive clinical behavior [17]. 
 
Sarcomatoid variant of adrenal cortical carcinoma.  
This is the rarest adrenal cortical carcinoma variant and to our knowledge only 14 cases have been 
reported in the literature so far. They have been classified as either sarcomatoid carcinomas with 
spindle cell areas [18,22] or carcinosarcomas in the presence of a specialized mesenchymal 
component, revealing osteosarcomatous [23,24], chondrosarcomatous [23], 
rhabdomyosarcomatous [25,28] and primitive neuroectodermal tumor-like [28] differentiation. 
Sarcomatoid carcinoma is highly aggressive and the recognition of diagnostic features of 
malignancy is not problematic. For this reason it was suggested a cut-off of 10% of sarcomatous 
component to diagnose this unusual variant, irrespective of the Weiss Score [21]. 
 
Pediatric adrenal cortical tumors.  
Pediatric adrenal cortical tumors are rarer than their adult counterparts, with an incidence which 
varies across geographic regions, being remarkably high in Southern Brazil, compared to the 
United States and Europe. The diagnosis of malignancy in pediatric adrenal cortical tumors is even 
more challenging than those of adults, because the Weiss Score criteria often lack sensitivity and 
specificity in pediatric cases. For this reason in 2003, Wieneke and coworkers [29] proposed 
categorizing pediatric adrenal cortical tumors into three different prognostic groups, “benign”, 
“indeterminate for malignancy” and “malignant”, according to the evaluation of nine parameters 
that were found the most statistically significant to predict malignant behavior. In this study, 
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among the classical criteria considered in the Weiss system, only confluent necrosis, capsular or 
vascular invasion, presence of atypical mitotic figures and a mitotic count >15 per 20 high power 
fields were significantly related to poor prognosis. Conversely, some others (eosinophilic 
cytoplasm, diffuse architecture or sinusoidal invasion) were apparently less relevant. Four 
additional parameters had also a significant impact on prognosis, including tumor weight >400 g, 
tumor size >10.5 cm, vena cava invasion and peri-adrenal tissue infiltration. The prognostic 
relevance of these parameters has recently been validated in the Italian Pediatric Rare Tumor 
(TREP) Study [30]. Moreover, in this latter series, the authors found that focal myxoid stromal 
changes, which were not included in the Wieneke system, were also suggestive of malignancy in 
pediatric tumors. 
 
Mixed cortico-medullary tumors.  
Mixed cortico-medullary adrenal tumors are rare, with fewer than 20 well-documented cases of 
mixed cortico-medullary adenomas. Most cases are benign and show a dual divergent 
differentiation, as confirmed by the concurrent expression of adrenal cortex and adrenal medulla 
markers. Moreover, a case showing mixed cortical and medullary histological characteristics, as 
well as gross and microscopic evidence of malignancy has recently been documented [31].  
 
IMMUNOPHENOTYPIC MARKERS  
 
In adrenal cortical tumor pathology, immunohistochemistry has chronologically become useful for 
the purpose of differential diagnosis, firstly between adrenal cortical carcinoma and extra-adrenal 
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neoplasms (renal cell carcinoma, melanoma, poorly differentiated metastatic carcinomas, 
retroperitoneal sarcomas) (Figure 3), then between adrenal cortical and other primary adrenal 
tumors (pheochromocytoma, PEComa), and more recently between adrenal cortical adenoma and 
carcinoma. In addition, some immunohistochemical markers have been proposed as prognostic 
tools, although few of them have so far been validated in independent cohorts.  
 
Diagnostic markers of adrenal cortical origin.  
Many malignant neoplasms metastasize to the adrenal gland including lung, gastrointestinal, renal 
and breast cancer, and melanoma [32], and reliable immunohistochemical markers are therefore 
required to establish the correct diagnosis. Adrenal cortical tumors are usually positive for a 
variety of markers that are common to several other malignancies, such as vimentin [33], and 
variably express cytokeratin and neuroendocrine markers, such as synaptophysin and 
neurofilament. Moreover, adrenal cortex as well as adrenocortical tumors nearly invariably 
express mesothelioma-related markers calretinin [34] and D2-40 [35], although the specificity for 
the adrenocortical origin of these markers is limited by their expression at a variable extent also in 
other neoplasms including abdominal ones (i.e.  renal cell carcinoma, ovarian carcinoma). 
In 1990, a monoclonal antibody (D11) highly specific for adrenal cortical tissue was described 
[36,37]. However, its immunoreactivity was later observed only in a small subset of adrenal 
cortical carcinomas, heavily restricting its use as a general marker for adrenal cortical derivation 
[38,39]. Moreover, D11 is no longer commercially available or otherwise accessible.  
Since 1998, Melan-A (MART-1) and alpha-inhibin have become the most commonly used markers 
to prove the adrenal cortical origin of a given lesion [40-44]. Alpha-inhibin was also demonstrated 
to reflect the hormonal secretion of the tumor, being more frequently and intensively expressed 
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in androgen secreting neoplasms [45]. However, both markers have a limited sensitivity and fail to 
recognize a significant proportion (28% for Melan A and 31% for alpha-inhibin) of adrenal cortical 
carcinomas.   
Although already described in 1995 by Sasano and coworkers [46], only recently has steroidogenic 
factor-1 (SF-1; also known as Ad4BP or NR5A1) progressively become the marker of choice to 
differentiate between tumors of adrenal cortical and non-adrenal cortical origin. Physiologically, it 
plays a key role in the development of steroidogenic tissues and in the regulation of steroid 
biosynthesis and was found to be over-expressed in most cases of childhood adrenal cortical 
tumors [47,48]. In 2010, Sbiera and coworkers [49] demonstrated in a very large series of cases 
that nuclear SF-1 staining is a highly sensitive and specific marker of adrenal cortical derivation, 
being restricted to steroidogenic tissues and related tumors. In their study, none of the 
pheochromocytomas nor of the tumors that usually metastasize to the adrenal gland were 
reactive to SF-1. The diagnostic accuracy of SF-1 was further validated by different groups [50] [51] 
[52] and this marker represents the best currently available tool in this diagnostic setting.  
Variants of adrenal cortical tumors usually have an immunohistochemical profile similar to the 
conventional type. SF-1, Melan A and alpha-inhibin are expressed in oncocytic and myxoid cases in 
proportions comparable to classic adrenal cortical tumors [17,51]; neurofilament, either as diffuse 
cytoplasmic or small paranuclear dots, are more frequently and extensively expressed in the 
myxoid variant [7]. It is noteworthy that in the sarcomatoid variant of adrenal cortical carcinoma 
Melan-A, synaptophysin and calretinin are expressed to a lower extent or lost in the sarcomatous 
areas. 
 
Diagnostic markers of malignancy.  
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In the last two decades, several studies have focused on the applicability of immunohistochemical 
markers as ancillary tools assisting morphology in the diagnosis between benign and malignant 
lesions. Some of these markers are related to specific genetic alterations occurring more 
frequently in adrenal cortical carcinomas than in adenomas, whereas others are related to 
different proliferative profiles within the spectrum of adrenal cortical tumors.  
To date, the proliferation marker Ki-67 is the sole immunohistochemical antibody which has 
steadily been reported useful in the differential diagnosis between adenoma and carcinoma [53-
60]. Our group recently proposed phospho-histone H3 immunostaining as an alternative, faster 
and reliable method to highlight mitotic figures, being specifically useful in cases with low mitotic 
activity [61]. Moreover, in this study both phospho-histone H3 and Ki-67 immunostainings showed 
a high inter-observer agreement.  
Among the variety of other markers reported in the literature, p53 immunoreactivity was found 
well correlated with the presence of TP53 gene mutations, which are found in 25-30% of sporadic 
adrenal cortical carcinomas, but not in adenomas. For this reason, it is of limited interest as a 
diagnostic tool because of a good specificity, but a very low sensitivity [60,62]. IGF-2 protein over-
expression has also been observed in a high proportion of adrenal cortical carcinomas and almost 
no adenomas [60] but it is not usually included in the diagnostic armamentarium because of the 
difficult interpretation of the labeling. 
 
Prognostic markers.  
As described for diagnostic markers, a variety of proteins have been explored as prognostic factors 
in adrenal cortical carcinoma, either associated with cell proliferation, adrenal cortical 
differentiation, genetic defects or specific characteristics of malignant tumors cells.  
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Ki-67 proliferation index has been investigated as a prognostic marker for several years [63,64]. In 
a recent study, Ki-67 proved to be superior to mitotic count in terms of prognosis of adrenal 
cortical carcinoma patients, at least with regard to overall survival, helping to stratify three 
subgroups of patients based on cut-offs of <20%, 20-50% and >50% [61]. Another promising 
prognostic marker is SF-1, that, apart from the above mentioned diagnostic role, has also been 
validated in multiple cohorts as a marker of poor prognosis when expressed at high levels [49] 
[51]. Possibly providing a molecular explanation for SF-1 protein over-expression in a proportion of 
adrenal cortical carcinomas, the NR5A1, the SF-1 gene, was found amplified in childhood adrenal 
cortical cancer [47,48] and chromosomal gains in chromosome 9q (where the SF-1 gene is located) 
have also been described in adults [65]. Future studies are therefore needed to clarify the 
prognostic role of NR5A1 gene amplification in adrenal cortical cancer.  
β-catenin nuclear staining is associated with deregulation of the Wnt/β-catenin signaling pathway 
and correlates with CTNNB1 (the β-catenin gene) mutations. Its prognostic role has been validated 
in two independent cohorts of adrenal cortical carcinomas [66]. More recently, Ronchi and 
coworkers showed that low protein levels of serum glucocorticoid kinase 1, but not of nuclear β-
catenin and phosphorylated AKT, were associated with poor overall survival in adrenal cortical 
carcinoma patients [67]. 
Several other molecules have also been reported to influence (at the protein expression level) the 
outcome of adrenal cortical cancer patients, including Matrix Metalloproteinase type 2 [68] and 
Glucose Transporter 1 [69], but have not yet been validated in additional studies. 
 
GENETICS OF ADRENAL CORTICAL DISEASES 
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Hyperplasia.   
Some thirty years ago a peculiar condition was described by Carney at Mayo Clinic, characterized 
by of multiple pigmented adrenal cortical nodules in association with other lesions (myxomas, 
psammomatous melanotic schwannomas, spotty pigmentation and blue nevi of the skin or 
mucosae, together with a variety of endocrine neoplasms) [70]. This seminal description was 
subsequently confirmed by several additional cases that have led in the past two decades to a 
better clinical and pathological characterization of this condition as part of the Carney complex. 
Moreover, different types of mutations of the PRKAR1A gene were identified as the genetic 
causative defect for this syndrome [71]. 
 
 Adrenal cortical tumors in familial cancer susceptibility syndromes.  
Even if the majority of adrenal cortical carcinomas arise in a sporadic setting, a minority of cases 
are associated with familial cancer syndromes, including the autosomal dominant Li-Fraumeni and 
Beckwith-Wiedemann syndromes and, more rarely, the Gardner syndrome, Multiple Endocrine 
Neoplasia type 1, Neurofibromatosis type 1 and the Carney complex [72] (Table 1). The 
association of adrenal cortical carcinoma with both the conditions that will subsequently be coded 
as the Li-Fraumeni and hereditary colon cancer syndromes had already been established in the 
eighties of last century [73,74], but little knowledge on the genetic background was available at 
that time.  
Li-Fraumeni syndrome is a rare autosomal dominant cancer predisposition syndrome associated 
with germline mutations in the tumor suppressor gene TP53 and subsequent loss of 
heterozygosity at 17p13.1 locus, which confers an increased susceptibility to sarcomas, breast 
cancer, brain tumors, leukemia and lymphoma. Adrenal cortical carcinoma however develops in 
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only 3–4% of patients with Li-Fraumeni syndrome, usually in childhood [72]. Common TP53 
mutations include Arg to His substitution at codon 175 (which codes for amino acids of the DNA 
binding site), and Arg to His at codon 337 (R337H) (coding for the oligomerization domain). The 
latter is classically observed in children of Southern Brazil [75,76], where the incidence of adrenal 
cortical carcinoma is 10 to 15 times higher than in the rest of the world. Screening for germline 
TP53 mutations in patients with apparently sporadic adrenal cortical carcinoma is recommended, 
especially in pediatric cases but also in adults, as 4% of cases were recently reported to bear a 
germline mutation [77]. 
 In Beckwith-Wiedemann Syndrome, various developmental abnormalities, such as macrosomia, 
exomphalos, macroglossia, abdominal wall defects, ear and renal anomalies, and cleft palate, can 
be associated with pediatric tumors in 5% of cases, including adrenal cortical carcinoma. Although 
the majority of cases with Beckwith-Wiedemann Syndrome arise de novo, 15% of them are 
inherited as the result of a defective genomic imprinting of 11p15.5 locus. This chromosomal 
region is usually subjected to a tissue-specific maternal imprinting, therefore, only the paternal 
allele is expressed [78]. In Beckwith-Wiedemann Syndrome, there is a loss of the maternal locus 
and a gain in the paternal locus. As a consequence, IGF-2 which is expressed on the paternal allele 
is over-represented whereas p57kip2 and H19 which are expressed on the maternal allele are 
defective [79]. 
Other inherited cancer syndromes associated with adrenal cortical tumors (indeed, more often 
adenomas than carcinomas and generally restricted to adult patients) are Multiple Endocrine 
Neoplasia type 1, Gardner syndrome and Neurofibromatosis type 1. In Multiple Endocrine 
Neoplasia type 1, inactivating mutations in the MEN1 gene, located in the chromosomal region 
11q13, are responsible for the development of pituitary tumors, parathyroid tumors and other 
neuroendocrine tumors. In addition, patients are also at risk of developing multiple lipomas, 
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angiomas, and adrenal cortical tumors. The most common adrenal cortical phenotype observed in 
Multiple Endocrine Neoplasia type 1 is unilateral or bilateral hyperplasia, while adenomas are less 
common and carcinomas very rare occurrences [80]. Gardner syndrome is an autosomal dominant 
disorder caused by mutations in the adenomatous polyposis coli (APC) gene. Apart from adrenal 
cortical carcinoma, which is very rare in this syndrome, patients develop gastrointestinal polyps, 
osteomas, soft tissue tumors, epidermal cysts, desmoid tumors, and periampullary cancer, as well 
as other endocrine malignancies such as the cribriform variant of papillary thyroid cancer.  
 
Sporadic adrenal cortical tumors.  
Gene mutations. Inactivating mutations in tumor suppressor genes and activating mutations in 
oncogenes responsible for familial cancer syndromes have also been found as somatic alterations 
in sporadic adrenal cortical tumors, with special reference to carcinomas [81]. Losses of the MEN1 
gene locus at 11q13, but very infrequent gene mutations, have been detected in sporadic adrenal 
tumors [82,83]. Somatic mutations of TP53 gene, as seen in Li-Fraumeni syndrome, as well as p53 
protein accumulation can be detected in sporadic tumors and have been considered as a marker 
of malignancy, being virtually absent in adenomas. Activation of the Wnt/β-catenin pathway as 
the result of CTNNB1 mutations has been documented in up to 40% of carcinomas, but also in a 
relevant proportion of adenomas [84,85], especially non-secreting and/or large size tumors [86]. 
Moreover, the presence of activating mutations in the CTNNB1 gene is associated with a worse 
outcome in adrenal cortical cancer patients [66]. Finally, somatic inactivating mutations or allelic 
losses of the PRKAR1A locus at 17q22–24, involved in the Carney complex, were also seen in 
sporadic cases of adrenal cortical adenoma and carcinoma [87].  
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However, a significant proportion of adrenal cortical tumors lacks known genetic defects, and 
therefore several studies have recently been conducted to clarify molecular mechanisms 
alternative to gene mutations in the pathogenesis of these tumors. Genomic, transcriptomic, and 
methylomic profiles have been reported in relatively large series of cases and helped to classify 
adrenal cortical tumor families with even prognostic implications and to distinguish benign from 
malignant forms. However, an integrative view able to incorporate all such information is still 
missing, thus making the huge amount of data available still poorly transferable into clinical 
practice.  
Chromosomal imbalances. A number of studies have shown that chromosomal aberrations are 
more frequent in malignant than in benign and hyperplastic adrenal cortical lesions. Gains, losses 
and amplifications can be detected with either comparative genomic hybridisation (CGH) or 
allelotyping techniques. An aneuploid DNA pattern was often associated with such chromosomal 
imbalances, although the value of DNA ploidy analysis is limited for both diagnostic and prognostic 
purposes [88]. In particular, gains in chromosomes 6q, 7q, 12q, and 19p, and losses in 
chromosomes 3, 8, 10p, 16q, 17q, and 19q, have been associated with a significantly worse 
survival of adrenal cortical cancer patients, independent of tumor size, tumor weight, and 
functional status of the tumor [89]. A strong relationship between tumor size and number of 
chromosomal aberrations was reported, with no gains or losses detectable in adenomas smaller 
than five cm; conversely, gains on chromosomes 4 and 5 and losses on 2, 11, 17 were apparently 
restricted to carcinomas having a size of 7-20 cm [90]. Overall, extensive genomic imbalances were 
encountered in carcinomas by means of CGH, indicating that the molecular pathogenesis of 
sporadic tumors is complex and that multiple genetic changes drive malignant transformation and 
tumor progression. A recent study on childhood adrenal cortical tumors, using SNP array profiling, 
identified recurrent alterations in loci comprising well-known oncogenes (MYC, MDM2, PDGFRA, 
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KIT, MCL1, BCL2L1) and tumor suppressors (TP53, RB1, RPH3AL), not yet associated to adrenal 
cortical carcinoma [91]. 
Transcriptomic analysis. The last decade has been characterized by the development of high-
throughput methods for wide gene expression profiling. Since the first study in 2003 [92] progress 
has been made in both the understanding of the pathogenesis of adrenal cortical tumors and 
more recently in the stratification of adrenal cortical carcinomas into prognostic groups.  
The early studies aimed at the definition and validation of a malignant signature [93-95]. An initial 
attempt was made by Slater et al. [95], who classified the tumors into two groups (benign and 
malignant), according to the Weiss Score and identified 74 genes differentially expressed in the 
two groups. However, by definition, using such an approach the gene signature of malignancy 
cannot be a better approach than the Weiss score, which is the reference. To overcome this 
limitation, other authors used the probability of recurrence as the reference [93]. Among genes of 
significant impact in this setting, general proliferation markers (cell cycle regulators and cell cycle 
effectors) common to all cancer types, and some adrenal cortical specific markers were identified. 
Among these latter, IGF2 gene resulted consistently up-regulated in adrenal cortical carcinomas in 
different transcriptome analyses, thus depicting a specific IGF2 cluster of cases associated also to 
up-regulation of other growth factors and growth factor receptor genes [59,93,96-98]. An 
alternative cluster was characterized by down-regulation of steroidogenic enzyme genes, such as 
CYP11A, CYP11B and HSD3B1 [93], and this cluster was as efficient as pathological evaluation, 
using a Weiss score cut-off value of 4. Later, deReynies et al. identified two genes, DGL7 and 
PINK1, as the best molecular predictors of malignancy [97]. All the above observations were then 
turned into prognostic stratification. Again, by means of unsupervised hierarchical clustering, 
different authors observed peculiar transcriptome characteristics capable of dividing adrenal 
cortical carcinomas into cases with bad or good prognosis [96,97,99]. In the paper by de Reynies 
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and coworkers [97] the BUB1B and PINK1 genes showed the best prognostic performance. 
Integrating transcriptome and mutational profiles, three subgroups of adrenal cortical carcinomas 
with different biological and clinical behavior may be identified: 1) the p53 group, encompassing 
all tumors with a TP53 mutation; 2) the β-catenin group, containing all tumors with deregulation 
of the Wnt/β-catenin pathway (apparently mutually exclusive with p53 group); 3) the remaining 
group, with neither p53 nor β-catenin altered pathways but enriched in cell cycle and metabolism 
genes [100,101]. 
MicroRNA profiling. MicroRNAs (miRNAs) are short noncoding RNAs, 18 to 25 nucleotides in 
length, which influence gene expression either by post-transcriptional regulation of gene 
expression leading to target mRNA degradation or by the repression of its translation with 
consequent decrease in the particular protein levels or even by up-regulation of their targets 
[102]. Several studies analyzed the miRNA expression profile in adrenal cortical neoplasms. They 
mainly aimed at finding out those useful in differentiating adenomas from carcinomas and to date, 
a long list of de-regulated miRNAs is available [103]. Among them, miR-483 (in both 3p and 5p 
isoforms) and miR-195 are those more consistently found over-expressed and downregulated, 
respectively, both at the tissue and serum levels. Data concerning the prognostic role of these two 
miRNAs are controversial, as they were described as defining a subgroup of carcinomas with a 
poor prognosis by one group only [104,105]. miR-210 is another miRNA which was reported 
upregulated by different groups. It is the miRNA most consistently induced under hypoxia and high 
levels were found associated with clinico-pathological parameters of aggressiveness (necrosis and 
high Ki-67 proliferation index) and a poorer survival (Duregon et al., submitted manuscript). 
DNA methylation profiling. The role of DNA hypermethylation in adrenal cortical tumorigenesis 
has been evaluated in some recent studies. Altered DNA methylation of the H19 promoter had 
already been shown to be involved in the abnormal expression of both H19 and IGF2 genes in 
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adrenal cortical carcinomas [106]. In contrast, promoter methylation of TP53 has been 
demonstrated not to be a significant event in the development of adrenal cortical carcinomas 
[107]. Recently, a significant DNA hypermethylation of the RASSF1A promoter in adrenal cortical 
carcinoma, but not in adenoma, has been described, suggesting an epigenetic mechanism for 
RASSF1A silencing in malignant adrenal cortical tumors [108]. However, most DNA methylation 
studies thus far have focused on individual genes. More recently, comprehensive genome-wide 
analysis of DNA methylation in benign and malignant adrenal cortical tumors has been performed, 
sometimes obtaining controversial results, possibly related to the different methodological 
approaches [109-111]. Moreover, Barreau and coworkers distinguished two clusters of adrenal 
cortical carcinomas based on CpG island methylation status, the “CIMP” (CpG island methylator 
phenotype) and “non-CIMP”, the former associated to a poorer prognosis [112]. 
  
Adenoma-Carcinoma sequence.   
Although there has been much progress in the last 25 years, it is still unclear whether adrenal 
cortical carcinomas evolve from adenomas following a definite molecular progression pathway. 
Long-term follow-up of incidentally discovered adrenal cortical neoplasms suggests that adenomas 
generally maintain a benign phenotype [113]. However the sequence adenoma-carcinoma has 
been occasionally postulated in single cases showing the morphological co-existence of an 
aggressive component embedded within an otherwise adenomatous tissue [114-115]. In addition, 
a recent study described a mouse model in which an induced stabilized β-catenin associated with 
elevated IGF-2 expression resulted in a temporal progression from increasing adrenal cortical 
hyperplasia to subsequent adenoma, and occasionally carcinoma, formation [116]. Finally, Ronchi 
et al recently provided the first genome-wide high resolution overview of chromosomal changes in 
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large series of adrenal cortical tumors, including adenomas and carcinomas [117]. Among the 
benign tumors, small isolated copy number gains were the most frequent genetic alterations and 
almost all of them were also present in several carcinomas, thus supporting the concept of a 
common early molecular signature. Moreover, the Wnt/β-catenin and Notch signaling pathways 
were commonly altered in both adenomas and carcinomas, strengthening their previous 
hypothesis that these pathways are involved in early tumor pathogenesis.  
 
 
FUTURE PERSPECTIVES: Issues for the next 25 years 
 
As summarized above, the pathological armamentarium for adrenal cortical disease – (and, more 
specifically for tumor characterization) has undergone a wide evolution in the past 25 years. All 
these achievements in the diagnostic approach and in the phenotypical characterization have 
allowed a better definition of the disease on the one hand, but have also raised new questions and 
opportunities for the next 25 years. An arbitrary list of issues to be covered in the near future 
includes: 
a) the prospective validation and implementation of the accuracy and reproducibility of the 
available diagnostic schemes; 
b) the definition of a grading system for adrenal cortical carcinomas, to further segregate cases 
associated with  “low” and “high” malignant potential; 
c) the identification and validation of markers predictive of tumor response and progression;  
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d) the identification of novel genetic alterations/pathways involved in adrenal cortical 
tumorigenesis, with special reference to the subset of cases with no current specific molecular 
signature; 
e) the integration of molecular, phenotypic, pathological and clinical data to design for  adrenal 
cortical tumor patients - as has been done for other human malignancies - individualized clinical 
management protocols. 
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Table 1. Summary of most relevant adrenal carcinoma-related inherited susceptibility 
syndromes. 
 Li-Fraumeni Beckwith-
Wiedemann 
Gardner MEN1 Carney Complex 
Tumor AC AC AA         
(rarely AC) 
AA         
(rarely AC) 
AA 
gene/locus TP53 
(17q13.1) 
alterated 
imprinting of 
11p15.5 
APC       
(5q21–22) 
MEN1 
(11q13) 
PRKAR1A 
(17q23–24) 
protein p53 IGF-II,  p57kip2 APC menin PRKAR1A 
 
Legend. AC: adrenal carcinoma; AA: adrenal adenoma 
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FIGURE LEGENDS 
 
Figure 1. Milestones in the pathological and molecular characterization of adrenal diseases in 
the past 25 years.  
 
Figure 2.  Pathological characteristics of a case of adrenal carcinoma (2.5 cm in the largest 
dimension) showing residual peripheral “adenomatous” features (left part in a, e, f, g; upper left 
corner in b). Carcinoma component showed reticulin disruption (b), atypical mitotic figures (c), 
increased mitotic index (as highlighted by phospho-histone H3, d) and increased Ki-67 index (e); 
adrenocortical markers  such as Melan A (f) and SF-1 (g) were  positive in both compionents. 
(original magnifications: 100x in all figures except c and d, 400x; a, c: H&E; b: silver staining; d: 
immunoperoxidase with AEC as chromogen; e, f, g: immunoperoxidase with diaminobenzidine as 
chromogen) 
 
Figure 3. Morphological and immunophenotypical profile of a breast carcinoma metastatic into 
an adrenal adenoma. Breast cancer cells (a to d, upper left corner) were immunoreactive for pan-
cytocheratins (b) and estrogen receptors (d) but negative for Melan A (c).  (original magnifications: 
200x in all figures; a: H&E; b-c-d: immunoperoxidase with diaminobenzidine as chromogen) 
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